PMU-Autor/inn/en
Aigner LudwigAbstract
There is a clinical need for plasma tests that can directly detect injury to pancreatic beta cells in type 1 diabetes. Such tests require biomarkers that are abundantly and selectively released into plasma by damaged beta cells. We combined LC-MS/MS proteomics and tissue-comparative transcriptomics of FACS-purified beta cells for bottom-up identification of candidate markers. Less than 10% of 467 proteins detected in beta cells showed endocrine-enriched expression. One surprising candidate was the neuronal migration marker doublecortin: in situ analysis revealed uniform doublecortin expression in the cytoplasm of all beta cells. Western blotting and real-time PCR confirmed its strong beta cell-selectivity outside the brain and its high molar abundance, indicating promising biomarker properties in comparison to GAD65, a more established marker of beta cell injury. DCX potential was validated in vitro: chemically-induced necrosis of rat and human beta cells led to a discharge of intracellular doublecortin into the extracellular space, proportionate to the amount of injured cells, and similar to GAD65. In vivo, recombinant DCX showed favorable pharmacokinetic properties, with a half-life in plasma of around 3h. Combined, our findings provide first proof-of-principle for doublecortin as biomarker for beta cell injury in vitro, advocating its further validation as biomarker in vivo.
Useful keywords (using NLM MeSH Indexing)
Animals
Biological Markers/analysis*
Glutamate Decarboxylase/blood
Humans
Insulin-Secreting Cells/metabolism
Insulin-Secreting Cells/pathology*
Microtubule-Associated Proteins/immunology
Microtubule-Associated Proteins/isolation*
purification
Microtubule-Associated Proteins/metabolism*
Neuropeptides/immunology
Neuropeptides/isolation*
purification
Neuropeptides/metabolism*
Proteomics
Rats
Transcriptome
Find related publications in this database (Keywords)
Insulin-secreting cells